Net Sales are expected to increase by 24 percent Y-o-Y (up 0.8 percent Q-o-Q) to Rs 5,050.3 crore, according to Nirmal Bang.

Zydus Lifesciences Q1 PAT may dip 10.6% YoY to Rs 505.2 cr: Prabhudas Lilladher

Net Sales are expected to decrease by 1.8 percent Y-o-Y (up 2.3 percent Q-o-Q) to Rs 3,953.9 crore, according to Prabhudas Lilladher.

Cadila Healthcare Q3 PAT seen up 3.2% YoY to Rs 544 cr: Prabhudas Lilladher

Net Sales are expected to decrease by 0.2 percent Y-o-Y (up 0.1 percent Q-o-Q) to Rs 3,788.1 crore, according to Prabhudas Lilladher.

Cadila Healthcare Q2 PAT seen up 19% YoY to Rs 563.3 cr: Prabhudas Lilladher

Net Sales are expected to decrease by 3.5 percent Y-o-Y (down 8.4 percent Q-o-Q) to Rs 3,685.8 crore, according to Prabhudas Lilladher.

Cadila Healthcare Q1 PAT seen up 63.9% YoY to Rs 744 cr: KRChoksey

Net Sales are expected to increase by 8.7 percent Y-o-Y (up 5.4 percent Q-o-Q) to Rs 3,956 crore, according to KRChoksey.

Cadila HC Q1 PAT seen up 10.7% YoY to Rs 502.5 cr: ICICI Direct

Net Sales are expected to increase by 5.4 percent Y-o-Y (down 0.3 percent Q-o-Q) to Rs 3,836.2 crore, according to ICICI Direct.

Cadila Q4 PAT seen up 13.7% YoY to Rs. 505 cr: Sharekhan

Net Sales are expected to increase by 2.5 percent Y-o-Y (up 1.3 percent Q-o-Q) to Rs. 3,844 crore, according to Sharekhan.

Cadila Healthcare Q3 PAT seen up 37.6% YoY to Rs. 373.9 cr: Prabhudas Lilladher

Net Sales are expected to increase by 5.3 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs. 3,638.1 crore, according to Prabhudas Lilladher.

Cadila Healthcare Q2 PAT may dip 23% YoY to Rs. 321.5 cr: Emkay

Net Sales are expected to increase by 17.4 percent Y-o-Y (down 0.6 percent Q-o-Q) to Rs. 3,475.2 crore, according to Emkay.

Cadila Healthcare Q1 PAT may dip 22.4% YoY to Rs. 366.7 cr: Prabhudas Lilladher

Net Sales are expected to increase by 13.9 percent Y-o-Y (down 11.7 percent Q-o-Q) to Rs. 3,296.1 crore, according to Prabhudas Lilladher.

Cadila Healthcare Q4 PAT may dip 28.9% YoY to Rs. 419.9 cr: Prabhudas Lilladher

Net Sales are expected to decrease by 3.6 percent Y-o-Y (down 12.4 percent Q-o-Q) to Rs. 3,134.8 crore, according to Prabhudas Lilladher.

Cadila Q3 PAT may dip 29.7% YoY to Rs. 382 cr: Sharekhan

Net Sales are expected to decrease by 6.7 percent Y-o-Y (up 2.8 percent Q-o-Q) to Rs. 3,043 crore, according to Sharekhan.

Cadila Healthcare Q3 PAT may dip 12.8% YoY to Rs. 473.7 cr: ICICI Direct

Net Sales are expected to decrease by 1.1 percent Y-o-Y (up 8.8 percent Q-o-Q) to Rs. 3,222.2 crore, according to ICICI Direct.

Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.

Cadila Healthcare Q2 PAT seen up 4.8% YoY to Rs. 530 cr: HDFC Securities

Net Sales are expected to decrease by 5.2 percent Y-o-Y (up 5.9 percent Q-o-Q) to Rs. 3,070 crore, according to HDFC Securities.

Cadila Q2 PAT may dip 23.3% YoY to Rs. 386 cr: Sharekhan

Net Sales are expected to decrease by 4.4 percent Y-o-Y (up 8.1 percent Q-o-Q) to Rs. 3,093 crore, according to Sharekhan.

Cadila Healthcare Q2 PAT may dip 25.4% YoY to Rs. 375.4 cr: ICICI Direct

Net Sales are expected to decrease by 7.6 percent Y-o-Y (up 3.2 percent Q-o-Q) to Rs. 2,986.6 crore, according to ICICI Direct.

Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

"For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities

Global brokerages upgrade these 6 stocks to buy post Q4 results

Global brokerage houses have upgraded a few stocks, highlighting robust Q4 FY18 results. Moneycontrol takes a look at six such stocks which have seen a ratings upgrade

Cadila Healthcare Q4 PAT seen up 36.5% YoY to Rs. 530 cr: HDFC Securities

Net Sales are expected to increase by 24 percent Y-o-Y (down 5.7 percent Q-o-Q) to Rs. 3,070 crore, according to HDFC Securities.

Cadila Healthcare Q4 PAT seen up 39.7% YoY to Rs. 538.4 cr: Edelweiss

Net Sales are expected to increase by 27.7 percent Y-o-Y (down 2.9 percent Q-o-Q) to Rs. 3,163.5 crore, according to Edelweiss.

Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.

Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.

Weak US sales, INR appreciation to drag earnings; Dr Reddy, Cadila top pick: Edelweiss

The USFDA granted 246 nods in Q3FY18, which is the highest-ever approvals in a single quarter. Cadila Healthcare received 23 and Aurobindo Pharma got 18 approvals.

Cadila Q4 PAT seen up 19.5% to Rs 309.7 cr: ICICI Securities

Net Sales are expected to increase by 5.8 percent Q-o-Q (down 0.4 percent Y-o-Y) to Rs 2434.2 crore, according to ICICI Securities. Cadila to report net profit at 309.7 crore up 19.5% quarter-on-quarter.